[1] Steensma DP, Bennett JM.The myelodysplastic syndromes: diagnosis and treatment[J]. Mayo Clin Proc,2006,81(1):104-130.
[2] Santini V, Girelli D, Sanna A, et al.Hepcidin levels and their determinants in different types of myelodysplastic syndromes[J]. PLoS One,2011,6(8):e23109.
[3] Ambaglio I, Malcovati L, Papaemmanuil E, et al.Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1[J]. Haematologica,2013,98(3):420-423.
[4] Porter JB, de Witte T, Cappellini MD, et al. New insights into transfusion-related iron toxicity: Implications for the oncologist[J]. Crit Rev Oncol Hematol,2016,99:261-271.
[5] Chung YJ, Robert C, Gough SM, et al.Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome[J]. Leuk Res,2014,38(1):95-102.
[6] Kikuchi S, Kobune M, Iyama S, et al.Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox[J]. Free Radic Biol Med,2012, 53(4):643-648.
[7] Gattermann N, Finelli C, Della Porta M, et al.Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes[J]. Haematologica,2012,97(9):1364-1371.
[8] Goldberg SL, Chen E, Corral M, et al.Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries[J]. J Clin Oncol,2010,28(17):2847-2852.
[9] Greenberg PL, Attar E, Bennett JM, et al.NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes[J]. J Natl Compr Canc Netw,2011,9(1):30-56.
[10] Armand P, Kim HT, Rhodes J, et al.Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation[J]. Biol Blood Marrow Transplant,2011,17(6):852-860.
[11] Carpenter JP, He T, Kirk P, et al.On T2* magnetic resonance and cardiac iron[J]. Circulation,2011,123(14):1519-1528.
[12] Zipperer E, Post JG, Herkert M, et al.Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome[J]. Ann Hematol,2013,92(12):1617-1623.
[13] Roth M, Will B, Simkin G, et al.Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation[J]. Blood,2012,120(2):386-394.
[14] Hartmann J, Braulke F, Sinzig U, et al.Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes[J]. Leuk Res,2013,37(3):327-332. |
